Ishara Investments LP

LOS ANGELES, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$119.5M2026 Q3+ $1.5M options (notional, not included)
Positions41
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.49.6%

Ishara Investments LP reported 41 positions worth $119.5M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: TVTX (7.1%). Biggest move: reduce XERS ($7.9M).

10 / 41 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 TVTXTravere Therapeutics$8.5M7.05%145,000——-15.6%
▸ 2 CYTKCytokinetics$8.4M6.97%128,000——-19.3%
▸ 3 BBIOBridgeBio Pharma$6.6M5.44%100,000——+16.7%
▸ 4 ACADAcadia Pharmaceuticals$6.4M5.33%320,000——-9.1%
▸ 5 TARSTarsus Pharmaceuticals$5.5M4.55%70,000——-0.5%
▸ 6 PTCTPTC Therapeutics$5.2M4.28%80,000——-5.9%
▸ 7 PRAXPraxis Precision Medicines$5.0M4.09%17,000——+6.5%
▸ 8 VERAVera Therapeutics$4.8M4.00%150,000——-18.9%
▸ 9 ARQTArcutis Biotherapeutics$4.8M3.93%180,000——+2.7%
▸ 10 ANNXAnnexon$4.7M3.92%1,120,000——-15.6%

Pro Feature

The remaining 31 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Ishara Investments LP hold as of Q3 2026?

Ishara Investments LP reported 41 positions worth $119.5M in its Q3 2026 13F filing. Largest positions: TVTX (7.1%), CYTK (7.0%), BBIO (5.4%), ACAD (5.3%) and TARS (4.5%).

What did Ishara Investments LP buy in Q3 2026?

New positions: TARS, PTCT, ARQT, UTHR and CELC (17 in all). Added to: CYTK, VERA, TVTX, NAMS and BBIO (12 in all).

What did Ishara Investments LP sell in Q3 2026?

Reduced: XERS, BMRN, PCVX, GMAB and ACAD (12 in all). Sold out entirely: AGIO, INSM, CRNXGBP, TNXP and KURA (17 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.